The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.
本公开涉及能够调节羟基类
固醇17-β
脱氢酶(H
SD17B)家族成员蛋白的化合物和药物组合物,包括抑制H
SD17B家族成员蛋白,例如H
SD17B13。本公开还涉及使用此处披露的化合物和药物组合物治疗肝脏疾病、障碍或状况的方法,其中H
SD17B家族成员蛋白发挥作用。